SERUM DOPAMINE‐β‐HYDROXYLASE IN SCHIZOPHRENIC PATIENTS

K. Fujita, T. Ito, K. Maruta, R. Teradaira, H. Beppu, Y. Nakacami, Y. Kato, T. Nagatsu, T. Kato

研究成果: Article査読

40 被引用数 (Scopus)

抄録

Abstract— Dopamine‐β‐hydroxylase (DBH) activity in serum was decreased significantly in schizophrenic patients (16.17 ± 12.60 μmol/min/1 of serum, mean ± S.D., n = 149) when compared with that of normal controls (42.53 ± 30.94 μmol/min/1 of serum, mean ± S.D., n= 153) and neurotic patients. Long duration of disease did not cause any significant changes in serum DBH activity except a tendency for increase in patients of lodger than 18 years duration. We also examined the possibility that the serum DBH deficiency in the schizophrenic group was an artifact of treatment with antipsychotic drugs, especially phenothiazines. No significant difference was observed between the patients treated with the drugs and the patients not receiving the drugs.

本文言語English
ページ(範囲)1569-1572
ページ数4
ジャーナルJournal of neurochemistry
30
6
DOI
出版ステータスPublished - 06-1978

All Science Journal Classification (ASJC) codes

  • 生化学
  • 細胞および分子神経科学

フィンガープリント

「SERUM DOPAMINE‐β‐HYDROXYLASE IN SCHIZOPHRENIC PATIENTS」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル